Compare MCW & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCW | ARDX |
|---|---|---|
| Founded | 1996 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.6B |
| IPO Year | 2021 | 2014 |
| Metric | MCW | ARDX |
|---|---|---|
| Price | $6.15 | $7.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 10 |
| Target Price | $7.59 | ★ $12.95 |
| AVG Volume (30 Days) | 1.0M | ★ 4.5M |
| Earning Date | 02-18-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.84 | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $1,041,660,000.00 | $398,234,000.00 |
| Revenue This Year | $6.86 | $22.44 |
| Revenue Next Year | $6.96 | $34.00 |
| P/E Ratio | $22.79 | ★ N/A |
| Revenue Growth | 6.98 | ★ 58.12 |
| 52 Week Low | $4.61 | $3.21 |
| 52 Week High | $8.60 | $8.40 |
| Indicator | MCW | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 62.31 | 51.35 |
| Support Level | $5.33 | $6.92 |
| Resistance Level | $6.24 | $8.02 |
| Average True Range (ATR) | 0.21 | 0.36 |
| MACD | 0.05 | -0.12 |
| Stochastic Oscillator | 89.06 | 23.31 |
Mister Car Wash Inc is a car wash brand offering express exterior and interior cleaning services. Express Exterior Locations offers express exterior cleaning services and Interior Cleaning Locations offers both express exterior and interior cleaning services. The company recognizes revenue from activities related to providing car wash services at its car wash locations that are geographically diversified throughout the United States and have similar economic characteristics and nature of services.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.